AUTHOR INDEX

(S = supplement; P = proceedings)

AARONS, L. *see* TOON, S.
AARONS, L. J. *see* GUENTERT, T. W.
AARSLAND, T. *see* DICKSTEIN, K.
ABRAHAMSEN, A. M. *see* DICKSTEIN, K.
ADDIS, G. J. *see* WHYTE, K. F.
ALLSOPP, L. A. *see* McINNES, G. T.
ALVÁN, G. *see* WALKER, O.
AL-WAIZ, M., MITCHELL, S. C., AYESH, R., IDLE, J. R. & SMITH, R. L. Variable N-oxidation of trimethylamine in man, 614P
AMBROSIONI, E., BORGHI, C. & COSTA, F. V. Captopril and hydrochlorothiazide: rationale for their combination, 43S
ANTAL, E. J. *see* KUBACKA, R. T.
ARDESCH, H. G. *see* MEIJER, J. L.
ARNOLD, J. M. O., LUDMER, P. L. & COLUCCI, W. S. Milrinone improves the vasodilator response to emotional stress in patients with severe heart failure, 628P
ARONSON, J. K. *see* KENNEDY, D. G.
ARONSON, J. K. *see* WOOD, A. J.
ASHFORD, J. J. Recent experience of ethics committee review of a multicentre research project, 373
ASMAR, R. G., PANNIER, B. M., HUGUE, CH. J., LAURENT, ST., SAFAVIAN, A. & SAFAR, M. E. Captopril + hydrochlorothiazide 24 h ambulatory monitoring effects, 77S
ATIBA, J. O., TAYLOR, G., PERSHE, R. A. & BLASCHKE, T. F. Plasma antipyrine half-life can be determined from urine data, 715
AXELSON, J. E., CHAN, G. L.-Y., KIRSTEN, E. B., MASON, W. D., LANMAN, R. C. & KERR, C. R. Food increases the bioavailability of propafenone, 735
AXELSON, J. E. *see* EDWARDS, D. J.
AYESH, R., OATES, N. S., HAYLER, A., WIDDOP, B., IDLE, J. R. & SMITH, R. L. Influence of oxidation polymorphism on the pharmacokinetics of tricyclic antidepressants in man, 645P
AYESH, R., SCADDING, G., MITCHELL, S. C., WARING, R. H., BROSTOFF, J., NEWSON-DAVIS, J., SEIFERT, M. H. & SMITH, R. L. Impaired sulphoxidation capacity and D-pencillamine-induced myasthenia gravis, 614P
AYESH, R. *see* AL-WAIZ, M.

BABER, N. S. *see* SCIBBERAS, D. G. J.
BACHMANN, K. Estimating the clearance of amylobarbitone from a single plasma measurement, 94
BACK, D. J. *see* BALL, S.
BACK, D. J. *see* KARBWANG, J.
BACK, D. J. *see* PURBA, H. S.
BACK, D. J. *see* ROGERS, S. M.
BACKER, N. V. *see* PEDERSEN, L. E.
BAILEY, P. M. *see* KAUFMAN, L.
BAINTON, D. *see* NEWRICK, P. G.
BALL, S., BACK, D. J., PURBA, H. S. & ORME, M. L'E. Inhibition of oestrogen 2-hydroxylase, 642P
BANJAR, W. *see* LONGMORE, J.
BARHAM, J. *see* HYER, S. L.
BARNES, A. J., CLARK, P. A., HUNT, W. B. & WILLARS, E. J. Effect of metformin on red blood cell flow properties in diabetes mellitus, 115P
BARNES, A. J., BUTT, G. R., CLARK, P. A., HUNT, W. B., PETTIT, K. L., THURGOOD, D. J. & WILLARS, E. J. A new filtration system for assessing drug effects on the flow properties of red and white blood cells, 125P
BARNES, N. C. *see* ZAKRZEWSKI, J. T.
BARNES, P. J. *see* DIXON, C. M. S.
BARNETT, D. B. *see* WALLEY, T. J.
BARR, S. M. *see* LEES, K. R.
BARRE, J., MALLAT, A., ROSENBAUM, J., DEFORGES, L., HOUIN, G., DHUMEAUX, D. & TILLEMENT, J.-P. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity, 753
BARRETT, M. L. *see* O'NEILL, L. A. J.
BARRY, M. G., MACMATHUNA, P., O'REILLY, T., DUENAS LAITA, A., KEELING, P. W. N. & FEELY, J. Effects of zinc supplementation on plasma protein binding and oxidative drug metabolism in chronic liver disease, 649P
BARRY, M. *see* MACMATHUNA, P.
BATEMAN, D. N. *see* GREVEL, J.
BATEMAN, D. N. *see* RODGERS, A.
BATEMAN, D. N. *see* TAYLOR, W. B.
BAULAC, L. *see* KAYANAKIS, J. G.
BAUR, M. P. *see* EICHELBAUM, M.
BAX, N. D. S., TUCKER, G. T. & WOODS, H. F. Indocyanine green kinetics in man—measurement by ear-piece densitometry, 646P
BEAN, B. E., CHANG, T. F., HUDSON, J. C. & RAMAN V. A statistical analysis of patterns of contraceptive practice in a local population, 119P
BEASLEY, C. R. W., HOVELL, C. J., MANI, R., ROBINSON, C. & HOLGATE, S. T. The comparative vascular effects of histamine, prostaglandin (PG)D_2 and its metabolite 9α 11β-$PGF_{2\alpha}$ in human skin, 605P
BEASLEY, C. R. W., VARLEY, J., ROBINSON, C. & HOLGATE, S. T. Direct and reflex bronchoconstrictor actions on prostaglandin (PG)D_2 and its initial metabolite 9α 11β-$PGF_{2\alpha}$ in asthma, 606P
BEASLEY, D. M. G. *see* EDWARDS, I. R.
BECKENBAUER, C. *see* HEIDEMANN, R.
BEERAHEE, A. *see* SMITH, S. R.
BELL, G. D., REEVE, P. A., MOSHIRI, M., MORDEN, A., COADY, T., STAPLETON, P. J. & LOGAN, R. F. A. Intravenous midazolam: a study of the degree of oxygen desaturation occurring during upper gastrointestinal endoscopy, 703
BELL, G. D., SPICKETT, G. P., REEVE, P. A., MORDEN,

A. & LOGAN, R. F. A. Intravenous midazolam for upper gastrointestinal endoscopy: a study of 800 consecutive cases relating dose to age and sex of patient, 241
BERNARD, F. *see* POGGI, L.
BERNHARD, H. *see* GENGO, F. M.
BHASKAR, N., BROWN, G., HAWKEY, C. J. & PRICHARD, P. J. Effect in man of dietary fatty acids on prostaglandin release and aspirin-induced gastric mucosal damage, 622P
BING, R. F. *see* WALLEY, T. J.
BIRKETT, D. J. *see* ROBSON, R. A.
BIRNIE, G. G., MCCOLL, K. E. L., THOMPSON, G. G., MOORE, M. R., GOLDBERG, A. & BRODIE, M. J. Antipyrine metabolism in acute hepatic porphyria in relapse and remission, 358
DIRNIE, G. G., THOMPSON, G. G., COOKE, A. & BRODIE, M. J. Antipyrine and indocyanine green kinetics in the prediction of the natural history of liver disease, 615P
BLASCHKE, T. F. *see* ATIBA, J. O.
BLAUW, G. J., VAN BRUMMELEN, P., CHANG, P. C., VEMEIJ, P. & VAN ZWIETEN, P. A. Effects of 5-hydroxytryptamine and ketanserin on the forearm vascular resistance in man, 631P
BLOOMFIELD, J. G. *see* KENNEDY, D. G.
BOCHNER, F. *see* SOMOGYI, A.
BOLAJI, O. O. *see* OGUNBONA, F. A.
BONDE, J., SVENDSEN, K., LYNGBORG, J., MEHLSEN, J. & TRAP-JENSEN, J. Immediate haemodynamic effects of a novel partial agonist, β_1-adrenoceptor blocking drug ICI 141 292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease, 35
BONDE, J. *see* PEDERSEN, L. E.
BONDESEN, S. *see* CHRISTENSEN, L. A.
BOOBIS, A. R., MURRAY, S., SPEIRS, C. J. & DAVIES, D. S. Dose dependent metabolism of phenacetin following oral administration, 643P
BORG, K.-O. *see* SEIDEMAN, P.
BORGHI, C. *see* AMBROSIONI, E.
BOSERUP, J. *see* CHRISTENSEN, L. A.
BOWES, S. G. *see* SMITH, M. A.
BOYE, G. L. *see* CRITCHLEY, J. A. J. H.
BRADBROOK, I. *see* FAZACKERLEY, E. J.
BRADBROOK, I. D., MAGNANI, H. N., MOELKER, H. C. T., MORRISON, P. J., ROBINSON, J., ROGERS, H. J., SPECTOR, R. G., VAN DINTHER, T. & WIJNAND, H. ORG 10172: A low molecular weight heparinoid anticoagulant with a long half-life in man, 667
BRADFORD, L. *see* FEELY, M.
BRADLEY, C. M. & NICHOLSON, A. N. Central effects of the H_1-receptor antagonist, loratidine, 637P
BRADSHAW, C. M. *see* LONGMORE, J.
BRADSHAW, E. G., DARK, C. H., SUER, A. H. & WALI, F. A. Atropine sulphate enhances neuromuscular transmission in anaesthetised patients, 636P
BRANDT, R. *see* GUENTERT, T. W.
BRAUN, L. A. *see* LENNARD, M. S.
BRECKENRIDGE, A. Introduction, 3S
BRECKENRIDGE, A. *see* WINSTANLEY, P.
BRECKENRIDGE, A. M. *see* KARBWANG, J.
BRECKENRIDGE, A. M. *see* WINSTANLEY, P. A.
BREWERTON, D. A. *see* DIXEY, J. J.
BROCKMEYER, N. H., KREUZFELDER, E., KIRCH, W., GOOS, M. & OHNHAUS, E. E. The effects of cimetidine on immune parameters in patients with AIDS related complex, 617P
BRODIE, M. J., MCPHAIL, E., MACPHEE, G. J. A., LARKIN, J. G. & GRAY, J. M. B. Psychomotor impairment in epilepsy—a consequence of the disease and its treatment, 609P
BRODIE, M. J. *see* BIRNIE, G. G.
BRODIE, M. J. *see* MACPHEE, G. J. A.
BRODIE, M. J. *see* MCCOLL, K. E.
BRODIE, M. J. *see* MCINNES, G. T.
BROOKS, P. M. *see* DAY, R. O.
BROSTOFF, J. *see* AYESH, R.
BROUGHTON PIPKIN, F. *see* LAWRENCE, M. R.
BROWN, G. *see* BHASKAR, N.
BRUNNER, H. R. Concluding remarks, 103S
BULLER, N. P. *see* SCOTT, S. C.
BUNCH, C. *see* WHITE, N. J.
BUNNAG, D. *see* KARBWANG, J.
BUNTINX, A. *see* VAN HECKEN, A. M.
BURSTEIN, E. S. *see* OCHS, H. R.
BUTT, G. R. *see* BARNES, A. J.
BUTTERS, L. *see* LEES, K. R.

CALAM, J. *see* UNWIN, R. J.
CAMERON, H. A., WALLER, P. C. & RAMSAY, L. E. Placebo-controlled trial of ketanserin in stable intermittent claudication, 597P
CAMERON, H. A., WALLER, P. C. & RAMSAY, L. E. The effect of ketanserin on the QT interval, 630
CAMI, J. *see* TARRUS, E.
CAMMELLI, L. *see* PONTIROLI, A. E.
CANEPA-ANSON, R., DAWSON, J. R., KUAN, P., POOLE-WILSON, P. A., SUTTON, G. C., COCKRILL, B. & REUBEN, S. R. Differences between acute and long-term metabolic effects of oral β-adrenoceptor agonist therapy with pirbuterol for cardiac failure, 173
CARRUTHERS, S. G. MCCALL, B., CORDELL, B. A. & WU, R. Relationship between heart rate and PR interval during physiological and pharmacological interventions, 259
CARRUTHERS, S. G. *see* FREEMAN, D. J.
CARSON, I. W. *see* MATHEWS, H. M. L.
CELDRAN, E. *see* TARRUS, E.
CELLE, G. *see* TESTA, R.
CHALLENOR, V. F., LE VIE, J., WALLER, D. G., GRUCHY, B., RENWICK, A. G. & GEORGE, C. F. Factors affecting the pharmacokinetics of nifedipine, 112P
CHALLENOR, V. F., WALLER, D. G., GRUCHY, B. S., RENWICK, A. G. & GEORGE, C. F. Food and nifedipine pharmacokinetics, 248
CHAN, G. L.-Y. *see* AXELSON, J. E.
CHANG, P. C., VAN VEEN, S., VERMEY, P. & VAN BRUMMELEN, P. β_1-adrenoceptor selectivity of bisoprolol compared with atenolol, 625P
CHANG, P. C. *see* BLAUW, G. J.
CHANG, T. F. *see* BEAN, B. E.
CHIBA, K. *see* ISHIZAKI, T.
CHILDS, M. *see* STERU, D.

CHOONARA, I. A., SHOO, E. E. & OWENS, G. G. Prescribing habits for children with acute gastroenteritis: a comparison over 5 years, 362
CHOUINARD, G. *see* LANGLOIS, S.
CHRISTENSEN, L. A., SLOT, O., SANCHEZ, G., BOSERUP, J., RASMUSSEN, S. N., BONDESEN, S., HANSEN, S. H. & HVIDBERG, E. F. Release of 5-aminosalicylic acid from Pentasa® during normal and accelerated intestinal transit time, 365
CIRILLO, V. J. *see* VAN HECKEN, A. M.
CLARK, P. A. *see* BARNES, A. J.
CLARKE, B. F. *see* REID, W.
COADY, T. *see* BELL, G. D.
COCKRILL, B. *see* CANEPA-ANSON, R.
COLBERT, J. *see* MAGGS, J. L.
COLLIER, R. & LINDUP, W. E. Drug binding effect of uraemic plasma: inhibitory effect of furanoid acids, 650P
COLLIER, P. S. *see* MATHEWS, H. M. L.
COLUCCI, W. S. *see* ARNOLD, J. M. O.
COMERFORD, M. B. & NYBERG, G. Anti-anginal efficacy of 5-isosorbide mononitrate 20 and 40 mg every 12 h in β-adrenoceptor blocked patients, 604P
COOKE, A. *see* BIRNIE, G. G.
COOKE, A. *see* FEELY, M.
COOPER, E. S. *see* CRITCHLEY, J. A. J. H.
COOPER, W. D. *see* KELLY, J. G.
COPELAND, S. *see* KONDOWE, G. B.
CORDELL, B. A. *see* CARRUTHERS, S. G.
COSTA, F. V. *see* AMBROSIONI, E.
COSTELLO, J. F. *see* ZAKRZEWSKI, J. T.
COULTER, D. M. *see* EDWARDS, I. R.
COWEN, P. J. *see* GLUE, P.
COWEN, P. J. *see* MCCANCE, S. L.
CREGEEN, R. J. *see* SCOTT, S. C.
CRITCHLEY, J. A. J. H., COOPER, E. S., BOYE, G. L., JOHNSTON, N. R., SAMSON, R. R. & LEE, M. R. Failure of negroes to increase urine dopamine following an oral sodium load, 113P
CROME, P. *see* PHILIP, P. A.

D'ARCY, P. F. *see* WARDLOW, P. W.
DAGNINO, F. *see* TESTA, R.
DAILLEY, C. *see* HAIGH, J. R. M.
DAMMANN, H. G. *see* KLOTZ, U.
DANA-HAERI, J. *see* WARRINGTON, S. J.
DARK, C. H. *see* BRADSHAW, E. G.
DARRAGON, T. *see* WEBER, S.
DAVIES, D. S. *see* BOOBIS, A. R.
DAWODU, A. H. *see* WALKER, O.
DAWSON, J. R. *see* CANEPA-ANSON, R.
DAY, R. O. & BROOKS, P. M. Variations in response to non-steroidal anti-inflammatory drugs, 655
DE BRUIJN, J. H. B. *see* MEIJER, J. L.
DE MEIRLEIR, K. J., GERLO, F., HOLLMANN, W. & VANHAELST, L. Cardiovascular effects of pergolide mesylate during dynamic exercise, 633P
DEERING, A. H., RIDDELL, J. G., HARRON, D. W. G. & SHANKS, R. G. Effect of acute administration of propranolol and atenolol on baroreceptor function in normal man, 624P
DEERING, A. H. *see* HARRON, D. W. G.
DEERING, A. H. *see* PRINGLE, T. H.
DEERING, A. H. *see* RIDDELL, J. G.
DEFORGES, L. *see* BARRE, J.
DEIGHTON, N. M. *see* ELLIOTT, H. L.
DE LAUTURE, D. *see* WEBER, S.
DEMERS, H. G. *see* KIRCH, W.
DENGLER, H. J. *see* EICHELBAUM, M.
DENGLER, H. J. *see* ISHIZAKI, T.
DENHAM, M. J. *see* SMITH, M. A.
DENHAM, M. J. *see* WARBURTON, A.
DE SCHEPPER, P. J. *see* VAN HECKEN, A. M.
DESGEORGES, M. *see* WEBER, S.
DHUMEAUX, D. *see* BARRE, J.
DI MARZO, V. *see* REES, M. C. P.
DICKSTEIN, K., TILL, A. E., AARSLAND, T., TJELTA, K., ABRAHAMSEN, A. M., KRISTIANSON, K., GOMEZ, H. G., GREGG, H. & HICHENS, M. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure, 403
DITISHEIM, A. *see* WEBER, S.
DIXEY, J. J., NOORMOHAMED, F. H., LANT, A. F. & BREWERTON, D. A. The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man, 55
DIXON, C. M. S., FULLER, R. W. & BARNES, P. J. The effect of angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects, 91
DOBBS, R. J. WARBURTON, A.
DOBBS, S. M. *see* SMITH, M. A.
DOBBS, S. M. *see* WARBURTON, A.
DOLLERY, C. T., FULLER, R. W., MALTBY, N. & TAYLOR, G. W. The effect of nafazatrom on allergen induced bronchoconstriction, 619P
DOLLERY, C. T. *see* FULLER, R. W.
DOLLERY, C. T. *see* WARREN, J.
DONNELL, D. *see* LIU, D. T. Y.
DONNELLY, R., ELLIOT, H. L., MEREDITH, P. A. & REID, J. L. Ketanserin in essential hypertension: haemodynamics, pharmacokinetics and pressor responses, 598P
DONOHOE, J. *see* KELLY, J. G.
DOROW, R. FG 7142 and its anxiety-inducing effects in humans, 781
DOW, R. J. *see* MACDONALD, F. C.
DOYLE, G. *see* KELLY, J. G.
DRIVET-PERRIN, J. *see* POGGI, L.
DUBINI, A. *see* PONTIROLI, A. E.
DUENAS LAITA, A. *see* MAGGS, M. G.
DUNDEE, J. W. Pharmacokinetics of midazolam, 591
DUNDEE, J. W. *see* MATHEWS, H. M. L.
DUNDEE, J. W. *see* MULLIGAN, K. R.
DUPONT, A. G. VANDERNIEPEN, P. & SIX, R. O. Effect of guanfacine on ambulatory blood pressure and its variability in elderly patients with essential hypertension, 397

EAST, S. *see* LANGLOIS, S.
EDWARDS, D. J., AXELSON, J. E., VISCO, J. P., VAN EVERY, S., SLAUGHTER, R. L. & LALK, A. D. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients, 351
EDWARDS, D. *see* PULLAR, T.
EDWARDS, G. *see* WINSTANLEY, P.
EDWARDS, G. *see* WHITE, N. J.

EDWARDS, I. R., COULTER, D. M., BEASLEY, D. M. G. & MACINTOSH, D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand, 529
EICHELBAUM, M., BAUR, M. P., DENGLER, H. J., OSIKOWSKA-EVERS, B. O., TIEVES, G., ZEKORN, C. & RITTNER, C. Chromosomal assignment of human cytochrome P-450 (desbrisoquine/sparteine type) to chromosome 22, 455
EICHELBAUM, M. *see* ISHIZAKI, T.
EL OMAR, E. *see* MCCOLL, K. E.
ELLIOTT, H. L., JONES, C. R., DEIGHTON, N. M., MEREDITH, P. A. & REID, J. L. Adomolol, a long acting β-adrenoceptor blocker in man, 511
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* SUMNER, D. J.
ENGELHARDT, M. *see* RIETBROCK, N.
ERICSSON, O. *see* WALKER, O.
ERKKOLA, R. *see* KANTO, J.
EWING, D. J. *see* REID, W.

FAGAN, S. C. *see* GENGO, F. M.
FAZACKERLEY, E. J., RANDALL, N. P. C., PLEUVRY, B. J., BRADBROOK, I. & MAWER, G. E. The respiratory effects of oral ethyl loflazepate in volunteers, 183
FEELY, J. *see* O'REILLY, T.
FEELY, J. *see* MACMATHUNA, P.
FEELY, J. *see* MAGGS, M. G.
FEELY, M., PRICE, D., PEAKER, S., BRADFORD, L., PULLAR, T. & COOKE, J. Low dose phenobarbitone as an indicator of compliance with antihypertensive therapy, 595P
FEELY, M. *see* HAIGH, J. R. M.
FEELY, M. P. *see* PULLAR, T.
FINLAYSON, J. *see* MACDONALD, F. C.
FLEMING, L. W., MORELAND, T. A., SCOTT, A. C. & STEWART, W. K. Ciprofloxacin penetration into peritoneal dialysis fluid, 653P
FORREST, G. *see* MCINNES, G. T.
FOX, J. *see* SCRIBBERAS, D. G. J.
FOX, J. S., WHITEHEAD, E. & SHANKS, R. G. Cardiovascular effects of the novel antihypertensive agent BRL 34915 in normal volunteers, 600P
FRAIS, M. A. *see* SILKE, B.
FRANSSEN, M. J. A. M. *see* VAN DEN OUWELAND, F. A.
FREDHOLM, B. B. *see* SEIDEMAN, P.
FREEMAN, D. J., MARTELL, R., CARRUTHERS, S. G., HEINRICHS, D., KEOWN, P. A. & STILLER, C. R. Cyclosporin–erythromycin interaction in normal subjects, 776
FREESTONE, S. *see* MACDONALD, T. M.
FREY, B. M. *see* GUENTERT, T. W.
FULLER, R. W., MALTBY, N., RICHMOND, R., DOLLERY, C. T., TAYLOR, G. W., RITTER, W. & PHILIPP, E. Oral nafazatrom in man: effect on inhaled antigen challenge, 677
FULLER, R. W., WARREN, J. B., MCCUSKER, M. & DOLLERY, C. T. Effect of enalapril on the skin response to bradykinin in man, 88
FULLER, R. W. *see* DIXON, C. M. S.
FULLER, R. W. *see* DOLLERY, C. T.
FULLER, R. W. *see* WARREN, J.

GARSTANG, F. M. *see* TOON, S.
GAYED, S. L. *see* PHILIP, P. A.
GELLER, A. *see* LUCKI, I.
GENGO, F. M., FAGAN, S. C., KROL, G. & BERNHARD, H. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls, 47
GENT, J. P. *see* HAIGH, J. R. M.
GEORGE, C. F. The Royal College of Physicians of London Reports, 251
GEORGE, C. F. *see* CHALLENOR, V. F.
GERLO, F. *see* DE MEIRLEIR, K. J.
GIESECKE, M. A. *see* LUCKI, I.
GILBERT, A. P., REED, P. L., THORNTON, P. C. & WAN, B. Y. C. Low dose carbenoxolone sodium in combination with theophylline—synergistic antiulcer activity in animals and man, 613P
GILBERT, L. M. *see* GREVEL, J.
GILBERT, R. J. & WILLIAMS, P. E. O. The oral retention and antiplaque efficacy of triclosan in human volunteers, 579
GILLIES, H. C., HERRIOTT, D., LIANG, R., OHASHI, K., ROGERS, H. J. & HARPER, P. G. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin IMI-30: NSC 256439) following intravenous and oral administration in patients with advanced cancer, 303
GIRARD, M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions, 73
GLOVER, D. R. *see* KELLY, J. G.
GLUE, P., NUTT, D. J., KOLAKOWSKA, T. & COWEN, P. J. Lithium enhances 5-HT-mediated neuroendocrine responses in man, 108P
GOLDBERG, A. *see* BIRNIE, G. G.
GOLDBERG, P. *see* HUGHES, A.
GOMEZ, H. J. *see* DICKSTEIN, K.
GOODCHILD, C. S. & NOBLE, J. The effects of intrathecal midazolam on sympathetic nervous reflexes in man—a pilot study, 279
GOOS, M. *see* BROCKMEYER, N.
GOTTLIEB, W. R. *see* KLOTZ, U.
GRAHAME-SMITH, D. G. *see* KENNEDY, D. G.
GRAHAME-SMITH, D. G. *see* MCCANCE, S. L.
GRAHAME-SMITH, D. G. *see* WOOD, A. J.
GRASSO, A. *see* TESTA, R.
GRAUDAL, N. A. *see* PEDERSEN, L. E.
GRAY, J. M. B. *see* BRODIE, M. J.
GREENBLATT, D. J. *see* OCHS, H. R.
GREGG, H. *see* DICKSTEIN, K.
GREVEL, J., GILBERT, L. M., TAYLOR, W. B., BATEMAN, D. N., KELMAN, A. W. & WHITING, B. Population pharmacokinetic analysis of metoclopramide in cancer patients, 618P
GRIBNAU, F. W. J. *see* VAN DEN OUWELAND, F. A.
GRIMMER, S. F. M. *see* ROGERS, S. M.
GRUCHY, B. S. *see* CHALLENOR, V. F.
GUENTERT, T. W., ØIE, S., PAALZOW, L., FREY, B. M., BRANDT, R., AARONS, L. J. & ROWLAND, M. Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs, 569
GUIDICELLI, J. F., RICHER, C. & MATTEI, A. Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients, 51S

HAGLUND, K. *see* SEIDEMAN, P.

HAIGH, J. R. M., PULLAR, T., GENT, J. P., DAILLEY, C. & FEELY, M. *N*-Desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?, 213
HAIGH, J. R. M. *see* PULLAR, T.
HALL, G. C. & WALKER, S. R. Adverse drug reaction monitoring by record linkage, 118P
HANKS, G. W. *see* JONES, V. A.
HANSEN, J.-E.S. *see* PEDERSEN, L. E.
HANSEN, S. H. *see* CHRISTENSEN, L. A.
HANSSON, L. Rationale for combination therapy, 15S
HARPER, P. G. *see* GILLIES, P. G.
HARRINGTON, C. I. *see* LENNARD, L.
HARRON, D. W. G., DEERING, A. H., MCCAFFREY, P., RIDDELL, J. G. & SHANKS, R. G. Effects of acute and chronic administration of diltiazem on baroreceptor function in normal man, 627P
HARRON, D. W. G. *see* DEERING, A. H.
HARRON, D. W. G. *see* PRINGLE, T. H.
HARRON, D. W. G. *see* RIDDELL, J. G.
HARRY, J. D. Research on healthy volunteers—a report of the Royal College of Physicians, 379
HARRY, J. D. *see* REID, W.
HASHIMOTO, Y. *see* ISHIZAKI, T.
HAWKEY, C. J. *see* BHASKAR, N.
HAYLER, A. *see* AYESH, R.
HEAGERTY, A. M. *see* WALLEY, T. J.
HEIDEMANN, R., BECKENBAUER, C. & WOODCOCK, B. G. Effect of posture on glyceryl trinitrate plasma concentrations following transdermal application, 246
HEINRICHS, D. *see* FREEMAN, D. J.
HERRIOTT, D. *see* GILLIES, H. C.
HICHENS, M. *see* DICKSTEIN, K.
HILLIS, W. S. *see* HORNUNG, R. S.
HOLGATE, S. T. *see* BEASLEY, C. R. W.
HOLLMANN, W. *see* DE MEIRLEIR, K. J.
HOLLY, M. *see* SIMPSON, K. H.
HOLZGREVE, H., OSTERKORN, K. & RUNGE, J. Captopril in combination with hydrochlorothiazide: comparative efficacy *vs* perceived best therapy, 93S
HOMBANJE, F. & SCOTT, A. K. Drug effects on determination of acetylator phenotype using sulphadimadine, 644P
HOPKINS, K. J. *see* TOON, S.
HORAI, Y. *see* ISHIZAKI, T.
HORNUNG, R. S. & HILLIS, W. S. The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction, 29
HORTH, C. E., LOBO, P. J. & WILSON, K. Computer assisted method for the analysis of plasma protein binding data, 122P
HORTH, C. E. *see* LOBO, P. J.
HORTON, M. A. *see* WARRINGTON, S. J.
HOSKIN, P. J. *see* JONES, V. A.
HOUIN, G. *see* BARRE, J.
HOUNSLOW, N. J., TAMRAZIANS, S., WISEMAN, W. T., MANN, S. & VANDENBURG, M. J. Use of a visual analogue meter, 117P
HOUNSLOW, N. J. *see* VANDENBURG, M. J.
HOVELL, C. J. *see* BEASLEY, C. R. W.
HOWARD, P. J. *see* MATHEWS, H. M. L.
HUDSON, J. C. *see* BEAN, B. E.
HUGHES, A., GOLDBERG, P. & SEVER, P. Dopamine does not mediate forearm vasodilatation due to atrial natriuretic peptide, 620P
HUGUE, CH. J. *see* ASMAR, R. G.
HUMPHREYS, F. & SHUSTER, S. The effect of topical dimethindene maleate on weal reactions, 234
HUNT, W. B. *see* BARNES, A. J.
HUNT, W. B. *see* SMITH, M. A.
HVIDBERG, E. F. *see* CHRISTENSEN, L. A.
HYER, S. L., TAYLOR, D., BARHAM, J., WILSON, J., SHAW, J. & VINCE, F. P. The effects of propranolol and metoprolol on skin blood flow in diabetic patients, 769

IBBA, R. *see* TESTA, R.
IDLE, J. R. *see* AL-WAIZ, M.
IDLE, J. R. *see* AYESH, R.
IKEDA, M. *see* MIYAMORI, I.
ISHIKAWA, A. *see* TANAKA, E.
ISHIZAKI, T., EICHELBAUM, M., HORAI, Y., HASHIMOTO, Y., CHIBA, K. & DENGLER, H. J. Evidence for polymorphic oxidation of sparteine in Japanese subjects, 482
ISHIZAKI, T. *see* OHNISHI, A.

JACK, D. B. *see* SMITH, S. R.
JACKSON, S. H. D., JAMIESON, M. J., JOHNSTON, A. & SHEPHERD, A. M. M. The analysis of dose-response curves—a practical approach, 199
JACKSON, N. *see* SILKE, B.
JACKSON, P. R. *see* LENNARD, M. S.
JAMES, C. A., MANT, T. G. K. & ROGERS, H. J. Pharmacokinetics of intravenous and oral sodium 2-mercapto-ethane sulphonate (mesna) in normal subjects, 561
JAMES, I. *see* SCIBBERAS, D. G. J.
JAMIESON, M. J. *see* JACKSON, S. H. D.
JEE, R. D. *see* WARBURTON, A.
JEFFERY, R. J. *see* MACDONALD, T. M.
JOHNSON, A. O. K. *see* WALKER, O.
JOHNSTON, A. *see* JACKSON, S. H. D.
JOHNSTON, A. *see* JONES, V. A.
JOHNSTON, G. D. *see* KONDOWE, G. B.
JOHNSTON, G. D. *see* PASSMORE, A. P.
JOHNSTON, N. R. *see* CRITCHLEY, J. A. J. H.
JONES, C. R. *see* ELLIOTT, H. L.
JONES, V. A., HOSKIN, P. J., OMAR, O. A., JOHNSTON, A., HANKS, G. W. & TURNER, P. Diamorphine stability in aqueous solution for subcutaneous infusion, 651P
JOSEPH THANGAM *see* SOMAJA, L.
JUHL, R. P. *see* KUBACKA, R. T.

KAMPMANN, J. P. *see* PEDERSEN, L. E.
KANGAS, L. *see* KANTO, J.
KANTO, J., ERKKOLA, R., KANGAS, L. & PITKANEN, Y. Placental transfer of flunitrazepam following intramuscular administration during labour, 491
KARBWANG, J., BACK, D. J., BUNNAG, D. & BRECKENRIDGE, A. M. Mefloquine pharmacokinetics when given alone or in combination with sulphadoxine and pyrimethamine in Thai subjects, 646P
KARBWANG, J., LOOAREESUWAN, S., PHILLIPS, R. E., WATTANAGOON, Y., MOLYNEUX, M. E., NAGA-

CHINTA, B., BACK, D. J. & WARRELL, D. A. Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination of mefloquine–sulphadoxine–pyrimethamine, 477
KARBWANG, J. *see* WHITE, N. J.
KAUFMAN, L. & BAILEY, P. M. Intravenous bumetanide attenuates the rise in plasma vasopressin concentrations during major surgical operations, 237
KAUSCH, M. *see* RIETBROCK, N.
KAYANAKIS, J. G. & BAULAC, L. Comparative study of once-daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension, 89S
KAYE, C. M., MANSON, J., MITCHELL, P. & PAGE, K. An h.p.l.c.–fluorescence method for the assay of perfloxacin and norfloxacin in plasma, 652P
KEAL, J. *see* SOMGYI, A.
KEELING, P. W. N. *see* MACMATHUNA, P.
KEELING, P. W. N. *see* O'REILLY, T.
KELLY, J. G., DOYLE, G., DONOHOE, J., LAHER, M., LONG, C., GLOVER, D. R. & COOPER, W. D. Acute and chronic dose pharmacokinetics of lisinopril effects of renal impairment, 629P
KELMAN, A. W. *see* GREVEL, J.
KELMAN, A. W. *see* MEREDITH, P. A.
KELWAY, B. *see* SIMPSON, K. H.
KENDALL, M. J. *see* SMITH, S. R.
KENNEDY, D. G., BLOOMFIELD, J. G., ARONSON, J. K. & GRAHAME-SMITH, D. G. The effect of low external potassium concentration on the Na/K-ATPase of human lymphoblasts, 639P
KEOHANE, P. *see* KLOTZ, U.
KEOWN, P. A. *see* FREEMAN, D. J.
KERR, C. R. *see* AXELSON, J. E.
KIRCH, W., DEMERS, H. G., ROSE, I., PABST, J. & OHNHAUS, E. E. Bisoprolol in renal failure, 623P
KIRCH, W., LOGEMANN, C., SANTOS, S. R. & OHNHAUS, E. E. Influence of different doses of nitrendipine on digoxin plasma concentrations, 111P
KIRCH, W. *see* BROCKMEYER, N.
KIRCH, W. *see* SANTOS, S. R.
KIRSTEN, E. B. *see* AXELSON, J. E.
KISHIMOTO, A. *see* OGURA, C.
KITTERINGHAM, N. R. *see* SANTOS, S. R.
KLOTZ, U. Pharmacokinetics of midazolam, 592
KLOTZ, U., DAMMANN, H. G., GOTTLIEB, W. R., WALTER, TH. A. & KEOHANE, P. Nizatidine (300 mg nocte) does not interfere with diazepam pharmacokinetics in man, 105
KOLAKOWSKA, T. *see* GLUE, P.
KONDOWE, G. B., COPELAND, S., LEAHEY, W. J. & JOHNSTON, G. D. The effect of chronic lisinopril therapy on blood pressure and intracellular calcium in patients with hypertension, 599P
KONGOLA, G., RIMMER, E. & RICHENS, A. Platelet GABA-transaminase activity in epileptic patients on vigabatrin therapy, 109P
KOSHIDA, H. *see* MIYAMORI, I.
KOSKI, J. *see* MATTILA, M. J.
KREEFT, J. H. *see* LANGLOIS, S.
KREUZFELDER, E. *see* BROCKMEYER, N.
KRISTIANSON, K. *see* DICKSTEIN, K.
KROL, G. *see* GENGO, F. M.
KUAN, P. *see* CANEPA-ANSON, R.
KUBACKA, R. T., ANTAL, E. J. & JUHL, R. P. The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics, 743
KUNIMOTO, N. *see* OGURA, C.

LAHER, M. *see* KELLY, J. G.
LALKA, D. *see* EDWARDS, D. J.
LANCRENON, S. *see* STERU, D.
LANGLOIS, S., KREEFT, J. H., CHOUINARD, G., ROSS-CHOUINARD, A., EAST, S. & OGILVIE, R. I. Midazolam: kinetics and effects on memory, sensorium, and haemodynamics, 273
LANGUILLAT, J. M. *see* STERU, D.
LANMAN, R. C. *see* AXELSON, J. E.
LANT, A. F. Evolution of diuretics and ACE inhibitors, their renal and hypertensive actions—parallels and contrasts, 27S
LANT, A. F. *see* DIXEY, J. J.
LARKIN, J. G. *see* BRODIE, M. J.
LARMA, I. *see* MATTILA, M.
LASAGNA, L. Lilly Prize Lecture. On assuring pharmacotherapeutic progress in the 21st century, 659
LAUFEN, H. & LEITOLD, M. Glyceryl-1-nitrate pharmacokinetics in healthy volunteers, 287
LAURENCE, D. R. The academic clinical pharmacologist and Royal College of Physicians Report on the relationship between physicians and the pharmaceutical industry, 253
LAURENT, ST. *see* ASMAR, R. G.
LAWRENCE, M. R. & BROUGHTON PIPKIN, F. Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy, 683
LEAHEY, W. J. *see* KONDOWE, G. B.
LEE, M. R. *see* CRITCHLEY, J. A. J. H.
LEE, M. R. *see* MACDONALD, T. M.
LEES, K. R., BARR, S. M., BUTTERS, L. & RUBIN, P. C. Ethanol and platelet intracellular free ionised calcium, 596P
LEES, K. R. & REID, J. L. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man, 159
LEITOLD, M. *see* LAUFEN, H.
LENNARD, L., HARRINGTON, C. I., WOOD, M. & MADDOCKS, J. L. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris, 229
LENNARD, M. S., LEWIS, R. V., BRAUN, L. A., RAMSAY, L. E., JACKSON, P. R., TUCKER, G. T. & WOODS, H. F. Timolol metabolism and debrisoquine oxidation phenotype, 644P
LE VIE, J. *see* CHALLENOR, V. F.
LEWIS, G. P. *see* O'NEILL, L. A. J.
LEWIS, R. V. *see* LENNARD, M. S.
LIANG, R. *see* GILLIES, H. C.
LINDUP, W. E. *see* COLLIER, R.
LIU, D. T. Y., SAVAGE, J. M. & DONNELL, D. Nefopam excretion in human milk, 99
LOBO, J. *see* SMITH, S. R.
LOBO, P. J., HORTH, C. E. & WILSON, K. Effect of lipophilicity on the plasma protein binding of some β-adrenoceptor antagonists, 120P

LOBO, P. J., HORTH, C. E. & WILSON, K. The effect of pH on the plasma protein binding of some β-adrenoceptor antagonists, 120P
LOBO, P. J., HORTH, C. E. & WILSON, K. Plasma propranolol concentrations and plasma protein binding in normal subjects after oral administration of propranolol, 121P
LOBO, P. J., HORTH, C. E. & WILSON, K. The interaction of canrenone, potassium canrenoate and SC-26304 with the plasma protein binding of sex steroids, 123P
LOBO, P. J. *see* HORTH, C. E.
LOCKE-HAYDON, J. *see* SCOTT, S. C.
LOGAN, R. F. A. *see* BELL, G. D.
LOGEMANN, C. *see* KIRCH, W.
LONG, C. *see* KELLY, J. G.
LONGMORE, J., BANJAR, W., SZABADI, E. & BRADSHAW, C. M. Antagonism of phenylephrine-evoked sweating by trazodone and amitriptyline in humans *in vivo*, 245
LONGMORE, J., THEOFILOPOULOS, N., SZABADI, E. & BRADSHAW, C. M. Modification of the pupillary light reflex by miotic and mydriatic drugs: applicability of model of functional interaction, 610P
LOOAREESUWAN, S. *see* KARBWANG, J.
LOOAREESUWAN, S. *see* WHITE, N. J.
LOUDON, J. M. *see* MCCLELLAND, G. R.
LUCKI, I., RICKELS, K., GIESECKE, M. A. & GELLER, A. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function, 207
LUDMER, P. L. *see* ARNOLD, J. M. O.
LYNGBORG, K. *see* BONDE, J.
LYONS, S. M. *see* MATHEWS, H. M. L.

MACDONALD, F. C., DOW, R. J., WILSON, R. A. G., YEE, K. F. & FINLAYSON, J. A study to determine potential interactions between nicardipine and propranolol in healthy volunteers, 626P
MACDONALD, T. M., JEFFREY, R. J., FREESTONE, S. & LEE, M. R. D-Sulpiride antagonises the renal effects of γ-l-glutamyl-l-dopa in man, 612P
MACGREGOR, G. A. The importance of the response of the renin-angiotensin system in determining blood pressure changes with sodium restriction, 21S
MACINTOSH, D. *see* EDWARDS, I. R.
MACMATHUNA, P., O'REILLY, T., BARRY, M., KEELING, P. W. N. & FEELY, J. Effect of combined β-adrenoceptor blockade and vasopressin on splanchnic and systemic haemodynamics in portal hypertension, 602P
MACMATHUNA, P. *see* BARRY, M. G.
MACMATHUNA, P. *see* O'REILLY, T.
MACPHEE, G. J. A., MITCHELL, J., WISEMAN, L., MCLELLAN, A. R., MCINNES, G. T. & BRODIE, M. J. Effect of sodium valproate on disposition and psychomotor profile of carbamazepine in healthy subjects, 639P
MACPHEE, G. J. A. *see* BRODIE, M. J.
MADDOCKS, J. L. *see* LENNARD, L.
MAGGS, J. L., COLBERT, J., WINSTANLEY, P. A., ORME, M. L'E. & PARK, B. K. Irreversible binding of amodiaquine to human liver microsomes: chemical and metabolic factors, 649P
MAGGS, J. L. *see* PURBA, H. S.
MAGNANI, H. N. *see* BRADBROOK, I. D.
MALLET, A. *see* BARRE, J.
MALTBY, N. *see* DOLLERY, C. T.
MALTBY, N. *see* FULLER, R. W.
MANGILI, R. *see* PONTIROLI, A. E.
MANI, R. *see* BEASLEY, C. R. W.
MANN, S. *see* HOUNSLOW, N. J.
MANSON, J. *see* KAYE, C. M.
MANT, T. G. K. *see* JAMES, C. A.
MARTELL, R. *see* FREEMAN, D. J.
MASON, W. D. *see* AXELSON, J. E.
MATHEWS, H. M. L., CARSON, I. W., LYONS, S. M., ORR, I. A. & DUNDEE, J. W. Plasma midazolam levels in children receiving midazolam infusion following open heart surgery, 634P
MATHEWS, H. M. L., ORR, I. A., LYONS, S. M., CARSON, I. W., COLLIER, P. S., HOWARD, P. J. & DUNDEE, J. W. Pharmacokinetics of midazolam in children undergoing heart surgery, 635P
MATTILA, M. & LARMA, I. A simple method for the administration of doxapram, 371
MATSUBARA, T. *see* MIYAMORI, I.
MATSUBAYASHI, M. *see* OGURA, C.
MATTEI, A. *see* GUIDICELLI, J. F.
MATTEI, A. *see* STERU, D.
MATTILA, M. J., KOSKI, J. & STROMBERG, C. Acute and subchronic effects of Org 2305 and diazepam on psychomotor performance in man, 219
MAWER, G. E. *see* FAZACKERLEY, E. J.
MCCAFFREY, P. *see* HARRON, D. W. G.
MCCAFFREY, P. M., RIDDELL, J. G. & SHANKS, R. G. The β-adrenoceptor partial agonist activity of cicloprolol in man by its effects on the CVS and finger tremor, 601P
MCCALL, B. *see* CARRUTHERS, S. G.
MCCANCE, S. L., COWEN, P. J. & GRAHAME-SMITH, D. G. Methergoline attenuates the prolactin responses to L-tryptophan, 607P
MCCANN, J. P., MCELNAY, J. C., NICHOLLS, D. P., SCOTT, M. G. & STANFORD, C. F. A pharmacokinetic and pharmacodynamic comparison of plain and enteric coated prednisolone tablets, 652P
MCCLELLAND, G. R., LOUDON, J. M. & RAPTOPOULOS, P. Paroxetine and oxazepam: effects on psychomotor performance, 117P
MCCLELLAND, G. R. & SHORTER, J. H. A microcomputer based system for the acquisition and analysis of electroencephalographic (EEG) data, 124P
MCCOLL, K. E., THOMPSON, G. G., EL OMAR, E., MOORE, M. R., PARK, B. K. & BRODIE, M. J. Effect of rifampicin on haem and bilirubin metabolism in man, 553
MCCOLL, K. E. L. *see* BIRNIE, G. G.
MCCOLLUM, J. S. C. *see* MULLIGAN, K. R.
MCCUSKER, M. *see* FULLER, R. W.
MCCUSKER, M. *see* WARREN, J.
MCELNAY, J. C. *see* MCCANN, J. P.
MCELNAY, J. C. *see* WARDLOW, P. W.
MCINNES, G. T., ALLSOPP, L. A. & BRODIE, M. J. Once daily oxprenolol for hypertension, 624P
MCINNES, G. T., FORREST, G., THOMPSON, G. G. & BRODIE, M. J. Measurements of amiloride in human

plasma and urine by a simplified h.p.l.c. procedure, 640P
McINNES, G. T. *see* MACPHEE, G. J. A.
MCKIERNAN, E. P. *see* NIGHTINGALE, J. J.
MCLELLAN, A. R. *see* MACPHEE, G. J. A.
MCPHAIL, E. *see* BRODIE, M. J.
MEHLSEN, J. *see* BONDE, J.
MEIJER, J. L., ARDESCH, H. G., VAN ROOIJEN, J. C. & DE BRUIJN, J. H. B. Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension, 83S
MENKE, G., PFISTER, P., SAUERWEIN, S., RIETBROCK, I., WOODCOCK, B. G. & RIETBROCK, N. Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods, 439
MEREDITH, P. A., KELMAN, A. W., SCOTT, P. J. W. & REID, J. L. Concentration-effect analysis and its application in age related studies, 605P
MEREDITH, P. A. *see* DONNELLY, R.
MEREDITH, P. A. *see* ELLIOTT, H. L.
MEREDITH, P. A. *see* SUMNER, D. J.
MIDTBO, K. *see* SILKE, B.
MIDTBO, K. A. *see* SILKE, B.
MILLET, B. *see* STERU, D.
MINEGISHI, A. *see* OHNISHI, A.
MINERS, J. O. *see* ROBSON, R. A.
MISAWA, S. *see* TANAKA, E.
MITCHELL, J. *see* MACPHEE, G. J. A.
MITCHELL, P. *see* KAYE, C. M.
MITCHELL, S. C. *see* AL-WAIZ, M.
MITCHELL, S. C. *see* AYESH, R.
MIYAMORI, I., IKEDA, M., MATSUBARA, T., OKAMOTO, S., KOSHIDA, H., YASUHARA, S. M., ORISE, T. & TAKEDA, R. The renal, cardiovascular and hormonal actions of human atrial natiuretic peptide in man: effects of indomethacin, 425
MOELKER, H. C. T. *see* BRADBROOK, I. D.
MOLYNEUX, M. E. *see* KARBWANG, J.
MOORE, M. R. *see* BIRNIE, G. G.
MOORE, M. R. *see* MCCOLL, K. E.
MORDEN, A. *see* BELL, G. D.
MORELAND, T. A. *see* FLEMING, L. W.
MORISE, T. *see* MIYAMORI, I.
MORRIS, H. R. *see* REES, M. C. P.
MORRISON, P. J. *see* BRADBROOK, I. D.
MOSHIRI, M. *see* BELL, G. D.
MILLIGAN, K. R., MCCOLLUM, J. S. C. & DUNDEE, J. W. An investigation into the antiemetic effect of propofol, 608P
MURRAY, S. *see* BOOBIS, A. R.

NAGACHINTA, B. *see* KARBWANG, J.
NEILSON, J. M. M. *see* REID, W.
NEWNHAM, D. *see* WEBSTER, J.
NEWRICK, P. G. & BAINTON, D. Benoxaprofen—adverse reactions and monitoring in general practice, 195
NEWSON-DAVIS, J. *see* AYESH, R.
NICHOLL, D. D. *see* WHITE, N. J.
NICHOLLS, D. P. *see* MCCANN, J. P.
NICHOLLS, P. J. *see* RAO, S.
NICHOLSON, A. N. *see* BRADLEY, C. M.
NICHOLSON, P. W. *see* WARBURTON, A.
NIGHTINGALE, J. J., STOCK, J. G. L., MCKIERNAN, E. P. & WILTON, C. T. Recovery after single breath halothane induction of anaesthesia: a comparison with i.v. thiopentone, 621P
NOBLE, J. *see* GOODCHILD, C. S.
NOORMOHAMED, F. H. *see* DIXEY, J. J.
NUTT, D. J. *see* GLUE, P.
NYBERG, G. *see* COMERFORD, M. B.

OATES, N. S. *see* AYESH, R.
OCHS, H. R., GREENBLATT, D. J. & BURSTEIN, E. S. Lack of influence of cigarette smoking on triazolam pharmacokinetics, 759
OGILVIE, R. I. *see* LANGLOIS, S.
OGUNBONA, F. A., ONYEJI, C. O., BOLAJI, O. O. & TORIMIRO, S. E. A. Excretion of chloroquine and desethylchloroquine in human milk, 473
OGURA, C., KISHIMOTO, A., KUNIMOTO, N., OMURA, F., MATSUBAYASHI, M. & TSUTSUI, T. Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers, 537
OHASHI, K. *see* GILLIES, H. C.
OHNHAUS, E. E. *see* BROCKMEYER, N.
OHNHAUS, E. E. *see* KIRCH, W.
OHNHAUS, E. E. *see* SANTOS, S. R.
OHNISHI, A., MINEGISHI, A., SASAKI, T., SUGANUMA, T. & ISHIZAKI, T. Effect of β-adrenoceptor blockade on exercise-induced plasma catecholamine concentrations and their dissipation profile, 339
ØIE, S. *see* GUENTERT, T. W.
OKAMOTO, S. *see* MIYAMORI, I.
OKAMURA, T. *see* TANAKA, E.
OLIVE, G. *see* WEBER, S.
OMAR, O. A. *see* JONES, V. A.
OMURA, F. *see* OGURA, C.
O'NEILL, C. J. A. *see* SMITH, M. A.
O'NEILL, C. J. A. *see* WARBURTON, A.
O'NEILL, J. A. J., BARRETT, M. L. & LEWIS, G. P. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect, 81
ONO, A. *see* TANAKA, E.
ONYEJI, C. O. *see* OGUNBONA, F. A.
O'REILLY, T., MACMATHUNA, P., KEELING, P. W. N. & FEELY, J. Indocyanine green pharmacokinetics in liver disease: comparison of two analytical methods, 647P
O'REILLY, T. *see* BARRY, M. G.
O'REILLY, T. *see* MACMATHUNA, P.
ORME, M. L'E. *see* BALL, S.
ORME, M. L'E. *see* MAGGS, J. L.
ORME, M. L'E. *see* PURBA, H. S.
ORME, M. L'E. *see* ROGERS, S. M.
ORME, M. L'E. *see* WINSTANLEY, P. A.
ORR, I. A. *see* MATHEWS, H. M. L.
OSIKOWSKA-EVERS, B. O. *see* EICHELBAUM, M.
OSTERKORN, K. *see* HOLZGREVE, H.
OWENS, G. G. *see* CHOONARA, I. A.

PAALZOW, L. *see* GUENTERT, T. W.
PABST, J. *see* KIRCH, W.
PAGE, K. *see* KAYE, C. M.

PAI, M. S. *see* STRUTHERS, A. D.
PANNIER, B. M. *see* ASMAR, R. G.
PARK, B. K. *see* MAGGS, J. L.
PARK, B. K. *see* MCCOLL, K. E.
PARK, B. K. *see* PURBA, H. S.
PASSMORE, A. P. & JOHNSTON, G. D. A comparison of the effects of ibuprofen and indomethacin on renal haemodynamics and electrolyte excretion, 611P
PASSMORE, P. *see* WARDLOW, P. W.
PEAKER, S. *see* FEELY, M.
PEAKER, S. *see* PULLAR, T.
PEART, W. S. *see* UNWIN, R. J.
PEDERSEN, L. E., BONDE, J. E., GRAUDAL, N. A., BACKER, N. V., HANSEN, J.-E. S. & KAMPMANN, J. P. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function, 41
PERSHE, R. A. *see* ATIBA, J. O.
PETRIE, J. C. *see* SCOTT, A. K.
PETRIE, J. C. *see* WEBSTER, J.
PETTIT, K. L. *see* BARNES, A. J.
PFISTER, P. *see* MENKE, G.
PHILIP, P. A., GAYED, S. L., ROGERS, H. J. & CROME, P. Influence of age, sex and body weight on the dapsone acetylation phenotype, 709
PHILIPP, E. *see* FULLER, R. W.
PHILLIPS, R. E. *see* KARBWANG, J.
PHILLIPS, R. E. *see* WHITE, N. J.
PIPER, P. J. *see* ZAKRZEWSKI, J. T.
PITKANEN, Y. *see* KANTO, J.
PLEUVRY, B. J. *see* FAZACKERLEY, E. J.
POGGI, L., VAISSE, B., BERNARD, F., DRIVET-PERRIN J. & SAMBUC, R. Comparison of once and twice daily administration of captopril plus hydrochlorothiazide on 24 h blood pressure levels, 71S
POHL, J. E. F. *see* WALLEY, T. J.
PONTIROLI, A. E., VIBERTI, G. C., MANGILI, R., CAMMELLI, L. & DUBINI, A. Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′-β-carbonyl)-urea-diphosphate (FCE 21336), 433
POOLE-WILSON, P. A. *see* CANEPA-ANSON, R.
PREADY, N. S. *see* SCOTT, S. C.
PRICE, D. *see* FEELY, M.
PRICHARD, P. J. *see* BHASKAR, N.
PRINGLE, T. H., DEERING, A. H., SCOTT, M. G., HARRON, D. W. G. & SHANKS, R. G. The assessment of the β-adrenoceptor blocking activity and cardioselectivity of H-I 42BS, a long acting β-adrenoceptor blocking drug, 411
PULLAR, T., EDWARDS, D., HAIGH, J. R. M., PEAKER S. & FEELY, M. P. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and *N*-desmethylclobazam, 317
PULLAR, T. *see* FEELY, M.
PULLAR, T. *see* HAIGH, J. R. M.
PURBA, H. S., BACK, D. J. & ORME, M. L'E. Inhibition of tolbutamide 4-hydroxylase, 641P
PURBA, H. S., MAGGS, J. L., ORME, M., BACK, D. J. & PARK, B. K. The metabolism of 7α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites, 447
PURBA, H. S. *see* BALL, S.

RAMAN, V. *see* BEAN, B. E.
RAMSAY, L. E. *see* CAMERON, H. A.
RAMSAY, L. E. *see* LENNARD, M. S.
RAMSAY, L. E. *see* WALLER, P. C.
RANDALL, N. P. C. *see* FAZACKERLEY, E. J.
RAO, S. & NICHOLLS, P. J. Effect of aminoglutethimide on platelet aggregation, 638P
RAPTOPOULOS, P. *see* MCCLELLAND, G. R.
RASMUSSEN, S. N. *see* CHRISTENSEN, L. A.
REED, P. I. *see* GILBERT, A. P.
REED, T. *see* UNWIN, R. J.
REES, M. C. P., DI MARZO, V., TIPPINS, J. R., MORRIS, H. R. & TURNBULL, A. C. Leukotriene release by human fetal membranes, decidua and placenta, 637P
REEVE, P. A. *see* BELL, G. D.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* ELLIOTT, H. L.
REID, J. L. *see* LEES, K. R.
REID, J. L. *see* MEREDITH, P. A.
REID, J. L. *see* SUMNER, D. J.
REID, J. L. *see* WHYTE, K. F.
REID, P. G., WATT, A. H., ROUTLEDGE, P. A. & SMITH, A. P. Intravenous infusion of adenosine but not inosine stimulates respiration in man, 331
REID, P. G. *see* WATT, A. H.
REID, W., EWING, D. J., HARRY, J. D., SMITH, H. J., NEILSON, J. M. M. & CLARKE, B. F. Effects of β-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy: a comparative study of epanolol, atenolol and pindolol, 383
REITBROCK, I. *see* MENKE, G.
RENWICK, A. G. *see* CHALLENOR, V. F.
REUBEN, S. R. *see* CANEPA-ANSON, R.
REY, E. *see* WEBER, S.
REYNOLDS, G. *see* SILKE, B.
RICHENS, A. *see* KONGOLA, G.
RICHER, C. *see* GUIDICELLI, J. F.
RICHMOND, R. *see* FULLER, R. W.
RICKELS, K. *see* LUCKI, I.
RIDDELL, J. G., DEERING, A. H. HARRON, D. W. G. & SHANKS, R. G. Do antihypertensive drugs affect the relationship between cuff and directly measured blood pressure, 594P
RIDDELL, J. G. *see* DEERING, A. H.
RIDDELL, J. G. *see* HARRON, D. W. G.
RIDDELL, J. G. *see* MCCAFFREY, P. M.
RIDDELL, J. G. *see* WARDLOW, P. W.
RIETBROCK, N., KAUSCH, M., ENGELHARDT, M., WOODCOCK, B. G. Non-bioequivalence of sublingual nifedipine, 589
RIETBROCK, N. *see* MENKE, G.
RIMMER, E. *see* KONGOLA, G.
RITTER, W. *see* FULLER, R. W.
RITTNER, C. *see* EICHELBAUM, M.
ROBB, O. J. *see* WEBSTER, J.
ROBERTS, D. J. *see* TYARRUS, E.
ROBINSON, C. *see* BEASLEY, C. R. W.
ROBINSON, J. *see* BRADBROOK, I. D.
ROBSON, R. A., MINERS, J. O., WHITEHEAD, A. G. & BIRKETT, D. J. Specificity of the inhibitory effect of

dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition, 772
RODGERS, A., WOODHOUSE, K. W. & BATEMAN, D. N. Effects of time of dosing and age on intravenous aminophylline pharmacokinetics, 344
RODICK, C. *see* WINSTANLEY, P. A.
ROGERS, H. J. *see* BRADBROOK, I. D.
ROGERS, H. J. *see* GILLIES, H. C.
ROGERS, H. J. *see* JAMES, C. A.
ROGERS, H. J. *see* PHILIP, P. A.
ROGERS, S. M., BACK, D. J. & ORME, M. L.'E. Intestinal metabolism of ethinyloestradiol and paracetamol *in vitro*: studies using Ussing chambers, 727
ROGERS, S. M., BACK, D. J., STEVENSON, P., GRIMMER, S. F. M. & ORME, M. L'E. Paracetamol interaction with oral contraceptive steroids, 615P
ROGERS, S. M., BACK, D. J., STEVENSON, P. J., GRIMMER, S. F. M. & ORME, M. L'E. Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol, 721
ROLAN, P. *see* SOMOGYI, A.
ROSE, I. *see* KIRCH, W.
ROSENBAUM, J. *see* BARRE, J.
ROSS-CHOUINARD, A. *see* LANGLOIS, S.
ROUTLEDGE, P. A. *see* REID, P. G.
ROUTLEDGE, P. A. *see* SHERIDAN, J. V.
ROUTLEDGE, P. A. *see* WATT, A. H.
ROWLAND, M. *see* GUENTERT, T. W.
ROWLAND, M. *see* TOON, S.
ROYSTON, J. P. *see* WARBURTON, A.
RUBIN, P. C. *see* LEES, K. R.
RUNGE, J. *see* HOLZGREVE, H.

SAFAR, M. E. *see* ASMAR, R. G.
SAFAVIAN, A. *see* ASMAR, R. G.
SALAKO, L. A. *see* WALKER, O.
SAMBUC, R. *see* POGGI, L.
SAMSON, R. R. *see* CRITCHLEY, J. A. J. H.
SANCHEZ, G. *see* CHRISTENSEN, L. A.
SANTOS, S. R., KIRCH, W., KITTERINGHAM, N. R. & OHNHAUS, E. E. Plasma levels and urinary excretion of digitoxin and its metabolites in patients with liver cirrhosis, 616P
SANTOS, S. R., KIRCH, W. & OHNHAUS, E. E. Urinary excretion of digitoxin and metabolites in healthy volunteers, 110P
SANTOS, S. R. *see* KIRCH, W.
SASAKI, T. *see* OHNISHI, A.
SAUERWEIN, S. *see* MENKE, G.
SAVAGE, J. M. *see* LIU, D. T. Y.
SCADDING, G. *see* AYESH, R.
SCHWEBIG, A. *see* STERU, D.
SCIBBERAS, D. G. J., FOX, J., JAMES, I. & BABER, N. S. The intradermal responses to injection of platelet activating factor (PAF) in man, 116P
SCOTT, A. C. *see* FLEMING, L. W.
SCOTT, A. K., WEBSTER, J. & PETRIE, J. C. Sorbinil pharmacokinetics in male and female elderly volunteers, 495
SCOTT, A. K. *see* HOMBANJE, F.
SCOTT, M. G. *see* MCCANN, J. P.
SCOTT, M. G. *see* PRINGLE, T. H.
SCOTT, P. J. W. *see* MEREDITH, P. A.
SCOTT, S. C., LOCKE-HAYDON, J., PREADY, N. S., BULLER, N. P. & CREGEEN, R. J. Ibopamine (SKF 100168) pharmacokinetics in relation to the timing of meals, 585
SEGURA, J. *see* TARRUS, E.
SEIDEMAN, P., BORG, K.-O., HAGLUND, K. & VON BAHR, C. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension, 267
SEIDEMAN, P., SOLLEVI, A. & FREDHOLM, B. B. Additive renal effects of indomethacin and dipyridamole in man, 323
SEIFERT, M. H. *see* AYESH, R.
SEVER, P. *see* HUGHES, A.
SEVERINS, J. P. *see* WEBER, S.
SHANKS, R. G. *see* DEERING, A. H.
SHANKS, R. G. *see* FOX, J. S.
SHANKS, R. G. *see* HARRON, D. W. G.
SHANKS, R. G. *see* MCCAFFREY, P. M.
SHANKS, R. G. *see* PRINGLE, T. H.
SHANKS, R. G. *see* RIDDELL, J. G.
SHARMA, S. K. *see* SILKE, B.
SHAW, J. *see* HYER, S. L.
SHELLEY, J. H. Relationships between physicians and the pharmaceutical industry: London College of Physicians 1986, 257
SHEPHERD, A. M. M. *see* JACKSON, S. H. D.
SHERIDAN, D. J. *see* SHERIDAN, J. V.
SHERIDAN, J. V., THOMAS, P., ROUTLEDGE, P. A. & SHERIDAN, D. J. Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris, 391
SHOO, E. E. *see* CHOONARA, I. A.
SHORTER, J. H. *see* MCCLELLAND, G. R.
SHUSTER, S. *see* HUMPHREYS, F.
SILKE, B., SHARMA, S. K., VERMA, S. P., MIDTBO, K. A. REYNOLDS, G. & TAYLOR, S. H. A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease, 165
SILKE, B., VERMA, S. P., MIDTBO, K., REYNOLDS, G., SHARMA, S., FRAIS, M. A. & TAYLOR, S. H. Comparison of five slow-calcium channel blocking drugs on haemodynamics in angina pectoris, 627P
SILKE, B., VERMA, S. P., REYNOLDS, G., SHARMA, S., JACKSON, N. & TAYLOR, S. H. Haemodynamic dose-response actions of cicloprolol in LV dysfunction due to ischaemic disease, 602P
SIMPSON, K. H., SMITH, R. J., KELWAY, B. & HOLLY, M. Effects of atropine and glycopyrrolate on cognition in volunteers, 620P
SIX, R. O. *see* DUPONT, A. G.
SJÖQVIST, F. *see* WALKER, O.
SLAUGHTER, R. L. *see* EDWARDS, D. J.
SLOT, O. *see* CHRISTENSEN, L. A.
SMITH, A. P. *see* REID, P. G.
SMITH, H. J. *see* REID, W.
SMITH, M. A., SULLENS, C. M., BOWES, S. G., O'NEILL C. J. A., HUNT, W. B., DENHAM, M. J. & DOBBS, S. M. Enalapril in heart failure in the very old, 114P
SMITH, R. L. *see* AL-WAIZ, M.
SMITH, R. L. *see* AYESH, R.
SMITH, R. J. *see* SIMPSON, K. H.

SMITH, S. R., KENDALL, M. J., LOBO, J., BEERAHEE, A., JACK, D. B. & WILKINS, M. R. Ranitidine and cimetidine: drug interactions with single dose and steady-state nifedipine administration, 311
SOARES DE MOURA, R. Effect of prostacyclin on the perfusion pressure and on the vasoconstrictor response of angiotensin II in the human isolated foetal placental circulation, 765
SOLLEVI, A. *see* SEIDEMAN, P.
SOMAJA, L. & JOSEPH THANGAM. Salivary paracetamol elimination kinetics during the menstrual cycle, 348
SOMOGYI, A., STOCKLEY, C., KEAL, J., ROLAN, P. & BOCHNER, F. Reduction of metformin renal tubular secretion by cimetidine in man, 545
SPECTOR, R. G. *see* BRADBROOK, I. D.
SPEIRS, C. J. *see* BOOBIS, A. R.
SPICKETT, G. P. *see* BELL, G. D.
SPICKETT, R. G. W. *see* TARRUS, E.
STANFORD, C. F. *see* MCCANN, J. P.
STAPLETON, P. J. *see* BELL, G. D.
STEPHAN, A. *see* STERU, D.
STEPHENS, M. R. *see* WATT, A. H.
STERU, D., CHILDS, M., LANCRENON, S., LANGUILLAT, J. M., MATTEI, A., MILLET, B., SCHWEBIG, A. & STEPHAN, A. Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension, 65S
STEVENSON, P. *see* ROGERS, S. M.
STEWART, W. K. *see* FLEMING, L. W.
STILLER, C. R. *see* FREEMAN, D. J.
STOCK, J. G. L. *see* NIGHTINGALE, J. J.
STOCKLEY, C. *see* SOMOGYI, A.
STROMBERG, C. *see* MATTILA, M. J.
STRUTHERS, A. D. & PAI, M. S. Evidence for a postsynaptic interaction between noradrenaline and angiotensin II in man, 597P
SUER, A. H. *see* BRADSHAW, E. G.
SUGANUMA, T. *see* OHNISHI, A.
SULLENS, C. M. *see* SMITH, M. A.
SUMNER, D. J. & ELLIOTT, H. L. The pressor dose-response in clinical cardiovascular pharmacology, 499
SUMNER, D. J., ELLIOTT, H. L., VINCENT, J. & REID, J. L. A pragmatic approach to the pressor-dose response as an index of vascular reactivity and adrenoceptor function, 505
SUMNER, D. J., MEREDITH, P. A., ELLIOTT, H. L. & REID, J. L. Initial blood pressure as a predictor of the response to antihypertensive therapy, 594P
SUTTON, G. C. *see* CANEPA-ANSON, R.
SVENDSEN, T. L. *see* BONDE, J.
SZABADI, E. *see* LONGMORE, J.

TAKEDA, R. *see* MIYAMORI, I.
TAMRAZIANS, S. *see* HOUNSLOW, N. J.
TAMRAZIANS, S. *see* VANDENBURG, M. J.
TAN, Y. *see* VAN DEN OUWELAND, F. A.
TANAKA, E., ISHIKAWA, A., ONO, A., OKAMURA, T. & MISAWA, S. Age-related changes in trimethadione oxidizing capacity, 355
TARRUS, E., CAMI, J., ROBERTS, D. J., SPICKETT, R. G. W., CELDRAN, E. & SEGURA, J. Accumulation of caffeine in healthy volunteers treated with furafylline, 9
TAYLOR, D. *see* HYER, S. L.
TAYLOR, G. *see* ATIBA, J. O.
TAYLOR, G. W. *see* DOLLERY, C. T.
TAYLOR, G. W. *see* FULLER, R. W.
TAYLOR, W. B. & BATEMAN, D. N. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochloroperazine in healthy volunteers, 137
TAYLOR, W. B. *see* GREVEL, J.
TESTA, M. A. Factors in the choice of antihypertensive therapy: techniques for clinical assessment and evaluation, 9S
TESTA, R., GRASSO, A., DAGNINO, F., IBBA, R., VARAGONA, G. & CELLE, G. Famotidine does not affect indocyanine green disposition and serum bile acid levels in healthy subjects, 779
THEOFILOPOULOS, N. *see* LONGMORE, J.
THOM, S. *see* UNWIN, R. J.
THOMAS, P. *see* SHERIDAN, J. V.
THOMPSON, G. G. *see* BIRNIE, G. G.
THOMPSON, G. G. *see* MCCOLL, K. E.
THOMPSON, G. G. *see* MCINNES, G. T.
THORNTON, P. C. *see* GILBERT, A. P.
THURGOOD, D. J. *see* BARNES, A. J.
TIEVES, G. *see* EICHELBAUM, M.
TILL, A. E. *see* DICKSTEIN, K.
TILLEMENT, J. P. *see* BARRE, J.
TIPPINS, J. R. *see* REES, M. C. P.
TJELTA, K. *see* DICKSTEIN, K.
TODD, G. R. G. *see* WARDLOW, P. W.
TOON, S., HOPKINS, K. J., GARSTANG, F. M., AARONS, L. & ROWLAND, M. Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly, 143
TORIMIRO, S. E. A. *see* OGUNBONA, F. A.
TRAP-JENSEN, J. *see* BONDE, J.
TSUTSUI, T. *see* OGURA, C.
TUCKER, G. T. *see* BAX, N. D. S.
TUCKER, G. T. *see* LENNARD, M. S.
TURNBULL, A. C. *see* REES, M. C. P.
TURNER, P. *see* JONES, V. A.

UNWIN, R. J., REED, T., THOM, S., CALAM, J. & PEART, W. S. Effects of indomethacin and (±)-propranolol on the cardiovascular and renin responses to vasoactive intestinal polypeptide (VIP) infusion in man, 523

VAISSE, B. *see* POGGI, L.
VAN BRUMMELEN, P. *see* BLAUW, G. J.
VAN BRUMMELEN, P. *see* CHANG, P. C.
VAN DEN OUWELAND, F. A., FRANSSEN, M. J. A. M., VAN DE PUTTE, L. B. A., TAN, Y., VAN, GINNEKEN, C. A. M. & GRIBNAU, F. W. J. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation, 189
VAN EVERY, S. *see* EDWARDS, D. J.
VAN GINNEKEN, C. A. M. *see* VAN DEN OUWELAND, F. A.
VAN HECKEN, A. M., VERBESSELT, R., BUNTINX, A., CIRILLO, V. J. & DE SCHEPPER, P. J. Absence of pharmacokinetic interaction between enalapril and frusemide, 84
VAN ROOIJEN, J. C. *see* MEIJER, J. L.
VAN VEEN, S. *see* CHANG, P. C.

VAN ZWIETEN, P. A. *see* BLAUW, G. J.
VANDENBURG, M. J. *see* HOUNSLOW, N. J.
VANDENBURG, M. J., HOUNSLOW, N. J., TAMRAZIANS, S. & WISEMAN, W. T. Difficulties of a visual analogue scale in the assessment of angina, 109P
VANDERNIEPEN, P. *see* DUPONT, A. G.
VAN DINTHER, T. *see* BRADBROOK, I. D.
VANHAELST, L. *see* DE MEIRLEIR, K. J.
VARAGONA, G. *see* TESTA, R.
VARLEY, J. *see* BEASLEY, C. R. W.
VERBESSELT, R. *see* VAN HECKEN, A. M.
VERE, D. W., Research on healthy volunteers—a report of the Royal College of Physicians, 375
VERMA, S. P. *see* SILKE, B.
VERMEIJ, P. *see* BLAUW, G. J.
VERMEY, P. *see* CHANG, P. C.
VIBERTI, G. C. *see* PONTIROLI, A. E.
VINCE, F. P. *see* HYER, S. L.
VINCENT, J. *see* SUMNER, D. J.
VISCO, J. P. *see* EDWARDS, D. J.
VISWALINGAM, A. *see* WOOD, A. J.
VON BAHR, C. *see* SEIDEMAN, P.

WALI, F. A. *see* BRADSHAW, E. G.
WALKER, O., DAWODU, A. H., SALAKO, L. A., ALVÁN, G. & JOHNSON, A. O. K. Single dose disposition of chloroquine in kwashiorkor and normal children—evidence for decreased absorption in kwashiorkor, 467
WALKER, O., SALAKO, L. A., ALVÁN, G., ERICSSON, O. & SJÖQVIST, F. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses, 295
WALKER, S. R. *see* HALL, G. C.
WALLER, D. G. *see* CHALLENOR, V. F.
WALLER, P. C. *see* CAMERON, H. A.
WALLER, P. C. *see* CAMERON, H. C.
WALLER, P. C. & RAMSAY, L. E. Rapid development of tolerance to the antihypertensive effect of nisoldipine, 603P
WALLEY, T. J., HEAGERTY, A. M., WOODS, K. L., BING, R. F., POHL, J. E. F. & BARNETT, D. B. Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers, 693
WALTER, TH. A. *see* KLOTZ, U.
WAN, B. Y. C. *see* GILBERT, A. P.
WARBURTON, A., ROYSTON, J. P., O'NEILL, C. J. A., NICHOLSON, P. W., JEE, R. D., DENHAM, M. J., DOBBS, S. M. & DOBBS, R. J. A quinine a day keeps the leg cramps away?, 459
WARDLOW, P. W., MCELNAY, J. C., PASSMORE, P., TODD, G. R. G., D'ARCY, P. F. & RIDDELL, J. G. Does kaolin and morphine mixture B.P. deplete body potassium, 631P
WARING, R. H. *see* AYESH, R.
WARRELL, D. A. *see* KARBWANG, J.
WARRELL, D. A. *see* WHITE, N. J.
WARREN, J., MCCUSKER, M., DOLLERY, C. T. & FULLER, R. W. Enalapril increases sensitivity to intradermal bradykinin, 110P
WARREN, J. B. *see* FULLER, R. W.
WARRINGTON, S. J., DANA-HAERI, J. & HORTON, M. A. Faecal blood loss during repeated administration of standard or sustained release tiaprofenic acid or Indocid® in men, 622P
WATT, A. H. *see* REID, P. G.
WATT, A. H., REID, P. G., STEPHENS, M. R. & ROUTLEDGE, P. A. Adenosine-induced respiratory stimulation in man depends on site of infusion. Evidence for an action on the carotid body?, 486
WATT, A. H. & ROUTLEDGE, P. A. Dipyridamole modulation of heart rate and ventilatory changes produced by intravenous adenosine boluses in man 632
WATTANAGOON, Y. *see* KARBWANG, J.
WEBER, S., DE LAUTURE, D., REY, E., DARRAGON, T., SEVERINS, J. P., DITISHEIM, A., OLIVE, G. & DEGEORGES, M. The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerine, 103
WEBSTER, J., NEWNHAM, D., ROBB, O. J. & PETRIE, J. C. Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide, 151
WEBSTER, J. *see* SCOTT, A. K.
WHITE, N. J., LOOAREESUWAN, S., EDWARDS, G., PHILLIPS, R. E., KARBWANG, J., NICHOLL, D. D., BUNCH, C. & WARRELL, D. A. Pharmacokinetics of intravenous amodiaquine, 127
WHITEHEAD, A. G. *see* ROBSON, R. A.
WHITEHEAD, E. *see* FOX, J. S.
WHITESMITH, R. *see* WHYTE, K. F.
WHITING, B. *see* GREVEL, J.
WHYTE, K. F., ADDIS, G. J., WHITESMITH, R. & REID, J. L. The mechanism of salbutamol-induced hypokalaemia, 65
WIDDOP, B. *see* AYESH, R.
WIJNAND, H. *see* BRADBROOK, I. D.
WILKINS, M. R. *see* SMITH, S. R.
WILLARS, E. J. *see* BARNES, A. J.
WILLIAMS, P. E. O. *see* GILBERT, R. J.
WILSON, J. *see* HYER, S. L.
WILSON, K. *see* HORTH, C. E.
WILSON, K. *see* LOBO, C. E.
WILSON, K. *see* LOBO, P. J.
WILSON, R. A. G. *see* MACDONALD, F. C.
WILTON, N. C. T. *see* NIGHTINGALE, J. J.
WINSTANLEY, P., EDWARDS, G., ORME, M. & BRECKENRIDGE, A. The disposition of amodiaquine in man after oral administration, 1
WINSTANLEY, P. A., RODICK, C., EDWARDS, G., ORME, M. L'E. & BRECKENRIDGE, A. M. Pharmacokinetics of amodiaquine after oral administration: effect of the dose size, 648P
WINSTANLEY, P. A. *see* MAGGS, J. L.
WISEMAN, L. *see* MACPHEE, G. J. A.
WISEMAN, W. T. *see* HOUNSLOW, N. J.
WISEMAN, W. T. *see* VANDENBURG, M. J.
WOOD, A. J., VISWALINGAM, A., ARONSON, J. K. & GRAHAME-SMITH, D. G. The effect of lithium on cation transport *in vivo* and *in vitro* in healthy volunteers, 609P
WOOD, M. *see* LENNARD, L.
WOODCOCK, B. G. *see* HEIDEMANN, R.
WOODCOCK, B. G. *see* MENKE, G.
WOODCOCK, B. G. *see* RIETBROCK, N.
WOODHOUSE, K. W. *see* RODGERS, A.
WOODS, H. F. *see* BAX, N. D. S.
WOODS, H. F. *see* LENNARD, M. S.
WOODS, K. L. *see* WALLEY, T. J.

WU, R. *see* CARRUTHERS, S. G.

YASUHARA, S. *see* MIYAMORI, I.
YEE, K. F. *see* MACDONALD, F. C.

ZAKRZEWSKI, J. T., BARNES, N. C., PIPER, P. J. & COSTELLO, J. F. Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay, 19
ZEKORN, C. *see* EICHELBAUM, M.

SUBJECT INDEX

(S = supplement; P = proceedings)

α_1-acid glycoprotein, 41, 569
9α 11β-$PGF_{2\alpha}$, 605P, 606P
Absorption, 477
Acetylation phenotype, 709, 644P
Adenosine, 331, 486, 632P
Adimolol, 511
Adrenoceptor function, 505
Adverse drug monitoring, 118P
Adverse reactions, 73, 195
Age, 241, 344, 495, 537, 605P, 709
Ageing, 439
Age-related, 355
AIDS related complex, 617P
Albumin, 439, 569
Alprenolol, 267
Ambulatory blood pressure, 397, 77S
Amiloride, 640P
Aminoglutethimide, 638P
Aminophylline, 344
5-Aminosalicylic acid, 365
Amitriptyline, 245
Amodiaquine, 1, 127, 648P, 649P
Analgesic, 99
Angina, 109P, 391, 604P
Angina pectoris, 627P
Angiotensin II, 597P, 765
Angiotensin converting enzyme inhibitors, 3S, 27S, 159, 403
ANP, 425
Anti-ulcer activity, 613P
Antiarrhythmic, 735
Anticoaglant, 667
Anticonvulsant, 213
Antidepressant, 537
Antihistamine, 234
Antihypertensive agents, 683
Antihypertensive drugs, 594P
Antihypertensive therapy, 5S, 9S, 594P, 595P
Antinatriuresis, 55
Antiplaque agent, 579
Antipyrine, 358, 615P, 715
Anxiety, 207, 780
Arterial hypertension, 15S, 51S, 77S, 89S
Assessment, 73
Asthma, 91, 606P
Atenolol, 411, 624P, 625P
Atrial natriuretic peptide, 620P
Atropine, 620P, 636P
Azathioprine, 229

β-adrenoceptor agonists, 173
β-adrenoceptor antagonism, 511
β-adrenoceptor antagonists, 120P
β-adrenoceptor blockade, 411, 602P
β-adrenoceptor blockers, 259, 383, 769
β_1-adrenoceptor blockade, 35
β_2-adrenoceptor, 65
Baroreceptor function, 624P, 627P
Bendrofluazide, 151
Benoxaprofen, 195
Benzodiazepine, 183
Benzodiazepines, 439
Bile acid, 779
Bilirubin, 553
Bioavailability, 735
Bioequivalence, 589
Biological effects, 51S
Bisoprolol, 623P, 625P
Blood pressure, 159, 425
Body weight, 709
Bradykinin, 88, 91, 110P
Breast milk, 473
BRL 34915, 600P
Bumetanide, 237
Buspirone, 207

Caffeine metabolism, 9
Calcium, 596P
Calcium antagonists, 259
Calcium channel blockers, 47, 683
Calcium channel blocking drugs, 627P
Canrenone, 123P
Captopril, 43S, 51S, 65S, 71, 77S, 83S, 93S, 123P, 529
Carbamazepine, 639P
Carbenoxolone sodium, 613P
Cardiac dysrhythmias, 65
Cardiac failure, 29
Cardioselectivity, 411
Carotid body, 486
Chloroquine, 295, 467, 473
Chromosome 22, 455
Cicloprolol, 601P, 602P
Cigarette smoking, 759
Cilastatin, 143
Cimetidine, 311, 317, 545, 617P, 743
Ciprofloxacin, 653P
Clinical effect, 491
Clinical pharmacokinetics, 189
Clinical pharmacologist, 253
Clobazam, 213, 317
Compliance, 595P
Concentration-effect analysis, 605P
Congestive heart failure, 403
Continuous monitoring, 65S
Contraception, 119P
Contraceptive steroids, 721
Converting enzyme inhibitors, 403
Coronary heart disease, 165
Cortisol, 433
Cyclic GMP, 425
Cyclosporin, 776
Cystic fibrosis, 19
Cytochrome P-450, 772
Cytokines, 81

Cytotoxic, 229

D-Aminolaevulinic acid synthase, 553
D-Pencillamine, 614P
D-Sulpiride, 612P
Dansylsarcosine, 439
Dapsone, 709
Debrisoquine oxidation phenotype, 644P
Decreased hepatic function, 41
Dentifrice, 579
Desethylchloroquine, 467
Desethylamodiaquine, 1, 295
Dextropropoxyphene, 772
Diabetes, 115P, 769
Diabetic autonomic neuropathy, 383
Diamorphine, 651P
Diazepam, 105, 207, 219
Digitoxin, 110P, 616P
Digoxin, 111P
Diltiazem, 165, 627P
Dimesna, 561
Dimethindene maleate, 234
Dipyridamole, 323, 632P
Disopyramide, 41
Diuretics, 27S, 89S
Diurnal variation, 344
Dopamine, 113Pm 62
Dose, 241
Dose-finding, 65S
Dose-response, 505
Dose-response curves, 199
Doxapram, 371
Drug administration, 371
Drug binding, 650P
Drug interaction, 545
Drug metabolism, 358
Drug monitoring, 41
Drug treatment, 15S

Ear-piece densitometry, 646P
EEG data analysis, 124P
Ethnic groups, 295
Elderly, 459
Elderly hypertensive patients, 397
Elderly volunteers, 143
Elimination kinetics, 348
Enalapril, 88, 151, 110P, 114P, 151, 403
Enalaprilat, 403
Enalaprilic acid, 29
Endoscopy, 703
Enzyme induction, 553
Epilepsy, 109P, 609P
Epinine, 585
Ergoline derivatives, 433
Erythromycin, 753, 776
Essential hypertension, 598P
Ethanol, 596P
Ethics committee, 373
Ethinyloestradiol, 447, 727
Ethyl loflazepate, 183
Exercise, 103, 259, 339

FG 7142, 780
Famotidine, 779
Fatty acids, 622P
Felodipine, 391
Feverfew, 81
Flunitrazepam, 491
Food effects, 585
Food, 248, 735
Free fatty acids, 439
Furafylline, 9
Furanoid acids, 650P

γ-L-Glutamyl-L-dopa, 612P
GABA, 109P
Gastric mucosal damage, 622P
Gastroenteritis, 362
Gene locus, 455
General practice, 195
Genetic polymorphism, 482
Glibenclamide, 743
Glyceryl-1-nitrate, 287
Glyceryl trinitrate, 246
Glycocholic acid, 569
Glycopyrrolate, 620P
Growth hormone, 433
Guanfacine, 397
Gut wall metabolism, 727

H-I 42 BS, 411
H_1-receptor antagonist, 637P
Haem biosynthesis, 553
Haemodynamics, 29, 35, 273, 391
Half-life, 715
Halothane, 621P
Healthy volunteers, 375, 379
Heart failure, 114P, 173, 628P
Heart rate, 159, 259, 383
Heparin, 667
Heparinoid, 667
Hepatic drug-oxidizing capacity, 355
High blood pressure, 21S
Histamine, 91, 605P
HOE 498, 91
Hormones, 173
Human foetal placental circulation, 765
Human milk, 99
Human trial, 219
5-HT, 108P
Hydrochlorothiazide, 43S, 51S, 55, 65S, 71S, 77S, 83S, 93S
5-Hydroxytryptamine, 631P
Hypertension, 43S, 65S, 83S, 93S, 151, 267, 599P, 624P
Hypolabuminaemia, 189
Hypokalaemia, 65

Ibopamine, 585
Ibuprofen, 611P
Idarubicin, 303
Imipenem, 143
Indocid®, 622P
Indocyanine green, 615P, 646P, 647P, 779
Indomethacin, 323, 425, 523, 611P
Inflammatory bowel disease, 365
Inhibition, 9

Inhibitors, 447
Initial dose effects, 151
Injection, 279
Inosine, 331
Interaction, 111P, 267, 569, 626P, 721, 776
Intermittent claudication, 597P
Intestinal transit time, 365
Intrathecal, 279
Intravenous infusion, 693
Intravenous kinetics, 287
Intrinsic sympathomimetic activity, 35
In vivo and *in vitro* studies, 511
Ischaemic disease, 602P
Isoprenaline, 259
5-Isosorbide mononitrate, 604P

Japanese, 482

Kaolin, 631P
Ketanserin, 597P, 598P, 630P, 631P
Kinetics, 439
Kininase II, 88
Kwashiorkor, 467

L-Tryptophan, 607P
Leg cramps, 459
Leukotriene B_4, 677
Leukotrienes, 19, 637P
LH, 433
Linear regression equations, 259
Linkage, 455
Lipophilicity, 120P
5-Lipoxygenase inhibitor, 677
Lisinopril, 599P, 629P
Lithium, 108P, 609P
Liver cirrhosis, 616P, 753
Liver disease, 47, 615P, 647P, 649P
Loratidine, 637P

Malaria, 127
Mefloquine, 477, 646P
Memory, 207, 273
Menstrual cycle, 348
Mesna, 561
2-Mercaptoethane sulphonate, 561
Metabolism, 1, 173, 229, 351, 772
Metformin, 115P, 545
Methergoline, 607P
Metoclopramide, 618P
Midazolam, 241, 279, 591, 592, 634P, 635P, 703
Midazolam pharmacokinetics, 273
Milrinone, 628P
Miotics, 610P
Mixed micelles, 569
Moderate arterial hypertension, 65S
Morphine, 631P
Multicentre research, 373
Myasthenia gravis, 614P
Mydriatics, 610P

N-Desmethylclobazam, 213, 217
N-Oxidation, 614P
Na/K-ATPase, 639P
Nafazatrom, 619P, 677
Naproxen, 55, 189
Natriuresis, 425
Nefopam, 99
Neonates, 439
Neuromuscular transmission, 636P
Nicardipine, 626P
Nifedipine, 112P, 248, 311, 589, 693
Nisoldipine, 603P
Nitrendipine, 111P
Nitroglycerine, 103
Nizatidine, 105
Non-steroidal anti-inflammatory drugs, 655
Noradrenaline, 523, 597P
Norfloxacin, 652P

Oestrogen 2-hydroxylase, 642P
Oral bioavailability, 287
Oral contraceptive steroids, 615P
ORG 2305, 219
ORG 10172, 667
Oxazepam, 117P
Oxidative drug metabolism, 649P
Oxprenolol, 624P
Oxygen desaturation, 703

P_1 blood group, 455
Paracetamol, 348, 615P, 721, 727
Paroxetine, 117P
Partial agonist activity, 383, 601P
Pentobarbitone, 267
Perfloxacin, 652P
Pergolide, 633P
Perindopril, 159
Pharmaceutical industry, 253, 257
Pharmacodynamics, 47, 693
Pharmacokinetics, 1, 47, 51S, 103, 105, 112P, 137, 143, 248, 295, 303, 317, 351, 365, 403, 495, 561, 585, 591, 592, 629P, 635P, 693, 743, 753, 759
Phenacetin, 643P
Phenobarbitone, 595P
Phenylephrine-evoked sweating, 245
Physicians, 257
Physiological tremor, 383
Pirbuterol, 173
Piretanide, 55
Pituitary, 433
Placental transfer, 491
Plasma catecholamines, 339
Plasma concentration, 183
Plasma glucose, 743
Plasma insulin, 743
Plasma protein binding, 491
Plasma, 715
Platelet activating factor, 116P
Platelet aggregation, 638P
Polymorphism, 455, 645P
Population pharmacokinetics, 618P
Porphobilinogen, 553
Porphyria, 358
Porphyrin, 553
Portal hypertension, 602P
Post-marketing surveillance, 529
Posture, 246
Potassium canrenoate, 123P

Potassium, 43S
Prednisolone, 652P
Pre-eclampsia, 683
Pregnancy, 683
Prescribing habits, 362
Prescription event recording, 195
Pressor dose-response, 499P
PR interval, 259
Prochlorperazine, 137
Prolactin, 433, 607P
Propafenone, 735
Propofol, 608P
Propranolol, 121P, 523, 624P, 626P
Prostacyclin, 765
Prostaglandin D_2, 605P, 606P
Prostaglandins, 622P
Prostanoids, 9
Protein binding, 41, 120P, 121P, 122P, 123P, 439, 569, 649P, 753
Protoporphyrinogen oxidase, 553
Psychomotor impairment, 219
Pupillary light reflex, 610P
Pyrimethamine, 477, 646P

QT interval, 630P
Quality of life, 9S
Quinidine, 351
Quinine, 459

Ramipril, 91
Ranitidine, 311, 743
Reactive metabolites, 447
Rechallenge, 73
Red blood cells, 125P
Reflexes, 279
Relationship, 241
Renal clearance, 545
Renal effects, 323
Renal excretion, 287
Renal failure, 623P
Renal function, 143
Renal haemodynamics, 611P
Renal impairment, 629P
Renin, 21S, 523
Renin-aldosterone, 159
Respiration, 331
Respiratory stimulation, 436
Rheumatoid arthritis, 81, 189
Rifampicin, 553
Royal College of Physicians Report, 253, 257
Royal College of Physicians, 375, 379

Salbutamol, 65
Saliva, 715
Salt, 21S
SC-26304, 123P
Selectivity, 625P
Sensorium, 273
Sex, 709
Skin blood flow, 769
Smoking, 351
Sodium, 43S
Sodium valproate, 639P
Sorbinil, 495
Sparteine oxidation, 455, 482
Sputum, 19
Sub-chronic study, 219
Subfractions, 41
Sulindac, 55
Sulphadimidine, 644P
Sulphadoxine, 477, 646P
Sulphoxidation, 614P
Surgical operations, 237

The Lilly Prize Lecture, 659
Theophylline, 323, 613P, 772
Thiopentone, 621P
Thiopurines, 229
Tiaprofenic acid, 622P
Timolol, 644P
Tolbutamide, 772
Tolbutamide 4-hydroxylase, 641P
Tolerance, 213, 603P
Topical availability, 365
Trazodone, 245
Triazolam, 759
Triclosan, 579
Tricyclic antidepressants, 645P
Trimethadione metabolism, 355
Trimethylamine, 614P
TSH, 433
Tubular secretion, 545

Uraemia, 41
Uricosuria, 55
Urine, 715

Vascular reactivity, 505
Vasoactive intestinal peptide, 523
Vasopressin, 237, 523, 602P
Ventilation, 183
Vigabatrin, 109P
Visual analogue meter, 117P
Visual analogue scale, 109P

Weal and flare, 88
Weal reactions, 234
White blood cells, 125P

Xenon clearance, 769

Y-8894, 537

Zinc, 649P